Raymond James Archives

Vintage comic-style illustration of three bulls pulling a loaded wagon through sunny farmland, with “EPRX” and “Trio of Bulls” above.

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. October 12, 2026 638Views 0Likes

Wall Street Price targets of $16, $17 and $18 seem to underscore the potential for a long-acting treatment as December clinical data approach Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has received a timely vote of confidence from three research firms, with newly…

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. October 2, 2026 777Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose…

FIGS Doubles Down on Healthcare Chic: Record Q4, Healthier Margins, and a Raymond James Runway -( $FIGS )

by John F. Heerdink, Jr. February 26, 2026 754Views 0Likes

FIGS just put up the kind of quarter that makes even seasoned healthcare investors sit up a little straighter in their ergonomic chairs. The direct‑to‑consumer scrubs innovator grew fourth‑quarter 2025 net revenues 33% year over year to a record 201.9 million dollars,…

Tag: Raymond James

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

FIGS Doubles Down on Healthcare Chic: Record Q4, Healthier Margins, and a Raymond James Runway -( $FIGS )

Your Guide To Staying Informed In The Markets